Updated privacy policy - GDPR
We are committed to protecting and safeguarding your personal data. We now meet the high standard for data privacy introduced by the new European data protection law known as the General Data Protection Regulation (GDPR) effective 25 May 2018.
You can review our policy at any time.
Our updated policy explains your rights under this new law, regarding how personal information is stored and processed. If you have any questions please don’t hesitate to contact us directly.
As always, thanks for being a part of our journey to make an impact on human wellbeing.
 effective 25 May...&media=//cdn.shopify.com/s/files/1/0767/9441/articles/AdobeStock_45062177_600x.jpeg?v=1528712348){kind=link}
Also in News
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
European patent for Trajan’s hemaPEN
US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.